Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Schizophrenia Information Center
Case Study: Ethics and Mental Illness in Pregnancy
A woman is evaluated by psychiatry on postpartum day 2 after staff noticed her talking to the mirror in her room and not showing affection to her newborn child. Case shows ethical decisions made when managing mental illness during pregnancy.
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Anhedonia Linked to Negative, Positive Symptoms in Schizophrenia
Three clusters detected corresponding to positive symptoms, negative symptoms and work functioning, and functional domains.
Response to Schizophrenia Treatment Varies Based on Genes
Investigators searched PubMed, Cochrane Library, Medline, Embase, CNKI, Weipu, and Wanfang databases for eligible studies through March 2022.
Genetics May Affect Pregnancy Risk Factors for Offspring Neurodevelopmental Conditions
Genetic liability to ADHD, schizophrenia linked to pregnancy-related factors thought to be associated with these conditions.
Can Machine Learning Better Stratify Patients With Early Psychosis?
To better identify and categorize symptoms, researchers developed a machine learning model to “redraw boundaries” within early psychosis.
Bipolar Disorder and Schizophrenia Show Similar Response Inhibition
Researchers sought to find mechanisms of impaired impulsivity control in patients with BD responding to emotion and compare them to patients with schizophrenia.
Continuous Theta Burst Stimulation Treats Auditory Hallucinations in Schizophrenia
For this study, patients with schizophrenia with auditory verbal hallucinations who had inadequate response to at least 1 antipsychotic drug were recruited.
Age- and Gender-Based Trends in Schizophrenia Onset
Investigators evaluated data collected for a population-based study of nearly 1.5 million adults that was conducted at seven sites across Australia.
Sleep Disturbance Variability Associated With Cognitive Performance in Schizophrenia
Investigators sought to further understand the link between cognitive dysfunction and disturbed sleep in patients with schizophrenia and determine future sleep interventions to improve functioning and disability.
Recognition of Fear, Anger Impaired in Psychosis Patients
Facial anger recognition was significantly associated with schizophrenia polygenic risk score.
Children With High Schizophrenia Familial Risk Have Differential Neurocognitive Maturation
Data for this analysis were sourced from the Danish High Risk and Resilience Study. Participants were identified through the Danish Civil Registration System and Danish Psychiatric Central Research Register.
Mental-Physical Multimorbidity Associates With Decreased Life Expectancy
In this study, mental disorders were determined using data from the Danish Psychiatric Central Research Register and general medical conditions from the Danish National Patient Register.
Psychiatric Disorders May Up SARS-CoV-2 Breakthrough Infection Risk
Among fully vaccinated adults, diagnosis of a psychiatric disorder linked to increased incidence of SARS-CoV-2 breakthrough infection.
Brexpiprazole May Improve Functioning in Patients With Schizophrenia
Some patients with schizophrenia may experience residual symptoms when treated with antipsychotics, due in part to their side effects. This analysis aims to examine both short-term improvement and residual symptoms of prescribed medication.
Repetitive Transcranial Magnetic Stimulation May Treat Cannabis Use Disorder in Schizophrenia
Outpatients with schizophrenia who were seeking treatment for cannabis use disorder were recruited between 2017 and 2020 at the Center for Addiction and Mental Health in Canada.
Schizophrenia, Bipolar Disorder Linked to Increased Cardiovascular Disease Risk
Researchers estimated the 10- and 30-year risk for cardiovascular disease in patients with serious mental illness.
Collaborative Care Key for Schizophrenia and Bipolar I Disorder Care During COVID-19
A panel of 15 experts and stakeholders reviewed findings of a systematic literature search and discussed the impact of the COVID-19 pandemic on mental health care, clinical practice, and management of individuals with schizophrenia and BP-I.
New Tool May Help Reduce CVD Risk in Patients With Mental Illnesses
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Schizophrenia Information Center
Loading... 
Loading...